BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer. 1992;66:558-562. [PMID: 1520594 DOI: 10.1038/bjc.1992.314] [Cited by in Crossref: 146] [Cited by in F6Publishing: 150] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Lacueva FJ, Calpena R, Medrano J, Teruel A, Mayol MJ, Graells ML, Camarasa MV, Perez-Vazquez MT, Ferragut JA. Changes in P-glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53. Cancer. 2000;89:21-28. [PMID: 10896996 DOI: 10.1002/1097-0142(20000701)89:1%3C21::AID-CNCR4%3E3.0.CO;2-T] [Reference Citation Analysis]
2 Kuczyk M, Bokemeyer C, Serth J, Hervatin C, Oelke M, Höfner K, Tan H, Jonas U. p53 overexpression as a prognostic factor for advanced stage bladder cancer. European Journal of Cancer 1995;31:2243-7. [DOI: 10.1016/0959-8049(95)00443-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
3 Mohiuddin M, Hayne M, Regine WF, Hanna N, Hagihara PF, McGrath P, Marks GM. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys. 2000;48:1075-1080. [PMID: 11072165 DOI: 10.1016/s0360-3016(00)00732-x] [Cited by in Crossref: 136] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
4 Misra S, Chaturvedi A, Goel MM, Mehrotra R, Sharma ID, Srivastava AN, Misra NC. Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol. 2000;26:164-167. [PMID: 10744937 DOI: 10.1053/ejso.1999.0763] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
5 Taniyama K, Sasaki N, Maruyama H, Nakai H, Nakatsuka H, Toyama K, Tahara E. Carcinoma Cells at Deeply Infiltrated Sites: Role in Development of Metastases in Patients with Advanced Colorectal Adenocarcinomas. In: Tahara E, editor. Molecular Pathology of Gastroenterological Cancer. Tokyo: Springer Japan; 1997. pp. 107-27. [DOI: 10.1007/978-4-431-65915-0_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
6 Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg. 1995;19:216-220. [PMID: 7754626 DOI: 10.1007/bf00308629] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kim KW, Kim N, Choi Y, Kim WS, Yoon H, Shin CM, Park YS, Lee DH, Park YS, Ahn SH, Park DJ, Kim HH, Lee HS, Kim JW, Kim JW, Lee KW, Chang W, Park JH, Lee YJ, Lee KH, Kim YH. Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study. Gastric Cancer 2021;24:844-57. [PMID: 33598811 DOI: 10.1007/s10120-021-01163-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Maehara Y, Emi Y, Tomisaki S, Oshiro T, Kakeji Y, Ichiyoshi Y, Sugimachi K. Age-related characteristics of gastric carcinoma in young and elderly patients. Cancer 1996;77:1774-80. [PMID: 8646673 DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1774::AID-CNCR3>3.0.CO;2-C] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
9 Okusa Y, Ichikura T, Tamakuma S. Immunohistochemical staining for the p53 protein and proliferating cell nuclear antigen in familial clustering of gastric cancer. J Surg Oncol 1996;62:253-7. [DOI: 10.1002/(sici)1096-9098(199608)62:4<253::aid-jso5>3.0.co;2-5] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
10 Starzynska T, Marsh P, Stern P. p53 Overexpression as a marker of malignancy in gastric biopsies. Surgical Oncology 1993;2:321-4. [DOI: 10.1016/0960-7404(93)90062-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
11 Müller W, Borchard F. PROGNOSTIC INFLUENCE OF p53 EXPRESSION IN GASTRIC CANCER. J Pathol 1996;178:255-8. [DOI: 10.1002/(sici)1096-9896(199603)178:3<255::aid-path468>3.0.co;2-v] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
12 Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S, Couture J. Molecular biology of colorectal cancer. Curr Probl Cancer. 1997;21:233-300. [PMID: 9438104 DOI: 10.1016/s0147-0272(97)80003-7] [Cited by in Crossref: 140] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
13 Paluszkiewicz P, Berbeć H, Pawłowska-wakowicz B, Cybulski M, Paszkowska A. p53 protein accumulation in colorectal cancer tissue has prognostic value only in left-sided colon tumours. Cancer Detection and Prevention 2004;28:252-9. [DOI: 10.1016/j.cdp.2004.05.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
14 Strang P, Nordström B, Nilsson S, Bergström R, Tribukait B. Mutant p53 protein as a predictor of survival in endometrial carcinoma. European Journal of Cancer 1996;32:598-602. [DOI: 10.1016/0959-8049(95)00636-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
15 Nardone G, Staibano S, Rocco A, Mezza E, D'armiento FP, Insabato L, Coppola A, Salvatore G, Lucariello A, Figura N. Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis. Gut. 1999;44:789-799. [PMID: 10323879 DOI: 10.1136/gut.44.6.789] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 4.2] [Reference Citation Analysis]
16 Carethers JM. THE CELLULAR AND MOLECULAR PATHOGENESIS OF COLORECTAL CANCER. Gastroenterology Clinics of North America 1996;25:737-54. [DOI: 10.1016/s0889-8553(05)70272-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
17 Taniyama K, Sasaki N, Wada S, Sasaki M, Miyoshi N, Nakai H, Kodama S, Nakatsuka H, Tahara E. Comparison of proliferative activities and metastases between two subtypes classified at the deeply infiltrating sites of colorectal moderately differentiated adenocarcinomas. Pathol Int 1996;46:195-203. [PMID: 10846570 DOI: 10.1111/j.1440-1827.1996.tb03598.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
18 Craanen ME, Blok P, Dekker W, Offerhaus GJ, Tytgat GN. Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 1995;36:848-52. [PMID: 7615272 DOI: 10.1136/gut.36.6.848] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 1.6] [Reference Citation Analysis]
19 Ishida M, Gomyo Y, Ohfuji S, Ikeda M, Kawasaki H, Ito H. Evidence that expression of a mutated p53 gene attenuates apoptotic cell death in human gastric intestinal-type carcinomas in vivo. Jpn J Cancer Res. 1997;88:468-475. [PMID: 9247603 DOI: 10.1111/j.1349-7006.1997.tb00405.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
20 Hwang HJ, Nam SK, Park H, Park Y, Koh J, Na HY, Kwak Y, Kim WH, Lee HS. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer. J Pathol Transl Med 2020;54:378-86. [PMID: 32601264 DOI: 10.4132/jptm.2020.06.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Saegusa M, Takano Y, Okayasu I. Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J Cancer Res Clin Oncol. 1995;121:357-363. [PMID: 7797601 DOI: 10.1007/bf01225688] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
22 Liu XP, Kawauchi S, Oga A, Suehiro Y, Tsushimi K, Tsushimi M, Sasaki K. Combined examination of p27(Kip1), p21(Waf1/Cip1) and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology. 2001;39:603-610. [PMID: 11903579 DOI: 10.1046/j.1365-2559.2001.01283.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
23 Liu XP, Tsushimi K, Tsushimi M, Oga A, Kawauchi S, Furuya T, Sasaki K. Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Pathol Int. 2001;51:440-444. [PMID: 11422805 DOI: 10.1046/j.1440-1827.2001.01216.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
24 Hardingham JE, Butler WJ, Roder D, Dobrovic A, Dymock RB, Sage RE, Roberts-Thomson IC. Somatic mutations, acetylator status, and prognosis in colorectal cancer. Gut 1998;42:669-72. [PMID: 9659162 DOI: 10.1136/gut.42.5.669] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
25 Fléjou JF, Gratio V, Muzeau F, Hamelin R. p53 abnormalities in adenocarcinoma of the gastric cardia and antrum. Mol Pathol 1999;52:263-8. [PMID: 10748875 DOI: 10.1136/mp.52.5.263] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
26 Chauhan S, Sen S, Chauhan SS, Pushker N, Tandon R, Kashyap S, Vanathi M, Bajaj MS. Stratifin in ocular surface squamous neoplasia and its association with p53. Acta Ophthalmol 2021. [PMID: 33769712 DOI: 10.1111/aos.14844] [Reference Citation Analysis]
27 Craanen ME, Blok P, Offerhaus GJ, Meijer GA, Dekker W, Kuipers EJ, Meuwissen SG. p21(Waf1/Cip1) expression and the p53/MDM2 feedback loop in gastric carcinogenesis. J Pathol 1999;189:481-6. [PMID: 10629547 DOI: 10.1002/(SICI)1096-9896(199912)189:4<481::AID-PATH482>3.0.CO;2-U] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
28 Ismail T, Hallissey MT, Fielding JWL. Pathologic prognostic factors for gastrointestinal cancer. World J Surg 1995;19:178-83. [DOI: 10.1007/bf00308623] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M. Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer. 1994;70:293-296. [PMID: 8054278 DOI: 10.1038/bjc.1994.295] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 1.7] [Reference Citation Analysis]
30 Mönig SP, Eidt S, Zirbes TK, Stippel D, Baldus SE, Pichlmaier H. p53 expression in gastric cancer: clinicopathological correlation and prognostic significance. Dig Dis Sci 1997;42:2463-7. [PMID: 9440620 DOI: 10.1023/a:1018844008068] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
31 Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Dig Dis Sci 1998;43:964-70. [PMID: 9590408 DOI: 10.1023/a:1018862214081] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Sgambato A, Migaldi M, Leocata P, Ventura L, Criscuolo M, Di Giacomo C, Capelli G, Cittadini A, De Gaetani C. Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas. Cancer 2000;89:2247-57. [DOI: 10.1002/1097-0142(20001201)89:11<2247::aid-cncr13>3.0.co;2-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
33 Poremba C, W. Yandell D, Mellin W, W. Schmid K, Reers B, Böcker W, Dockhorn-dworniczak B. Adenocarcinoma of the Cardia in a Young Man: Detection of Somatic p53 Mutation by Immunohistochemistry and Automated Direct Sequencing. Pathology - Research and Practice 1995;191:1004-9. [DOI: 10.1016/s0344-0338(11)80599-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Ahmed IA, Kelly SB, Anderson JJ, Angus B, Challen C, Lunec J. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer. Colorectal Dis 2008;10:344-51. [PMID: 17949449 DOI: 10.1111/j.1463-1318.2007.01317.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
35 Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, Jonas U. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995;71:201-5. [PMID: 7819040 DOI: 10.1038/bjc.1995.41] [Cited by in Crossref: 93] [Cited by in F6Publishing: 74] [Article Influence: 3.6] [Reference Citation Analysis]
36 Gonçalves AR, Carneiro AJ, Martins I, de Faria PA, Ferreira MA, de Mello EL, Fogaça HS, Elia CC, de Souza HS. Prognostic significance of p53 protein expression in early gastric cancer. Pathol Oncol Res 2011;17:349-55. [PMID: 21116760 DOI: 10.1007/s12253-010-9333-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
37 Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, Slattery ML. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer. 2002;99:597-602. [PMID: 14985740 DOI: 10.1002/ijc.10405] [Cited by in Crossref: 98] [Cited by in F6Publishing: 87] [Article Influence: 5.8] [Reference Citation Analysis]
38 Oiwa H, Maehara Y, Ohno S, Sakaguchi Y, Ichiyoshi Y, Sugimachi K. Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 1995;75:1454-9. [DOI: 10.1002/1097-0142(19950315)75:6+<1454::aid-cncr2820751511>3.0.co;2-g] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
39 Moghbeli M, Moaven O, Memar B, Raziei HR, Aarabi A, Dadkhah E, Forghanifard MM, Manzari F, Abbaszadegan MR. Role of hMLH1 and E-cadherin promoter methylation in gastric cancer progression. J Gastrointest Cancer. 2014;45:40-47. [PMID: 24022108 DOI: 10.1007/s12029-013-9548-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
40 Iwase T, Kushima R, Mukaisho K, Mitsufuji S, Okanoue T, Hattori T. Overexpression of CD10 and reduced MUC2 expression correlate with the development and progression of colorectal neoplasms. Pathol Res Pract. 2005;201:83-91. [PMID: 15901128 DOI: 10.1016/j.prp.2004.09.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
41 D'Andrea E, Baffa R, Menin C, Montagna M, Rugge M, Chieco-Bianchi L. TP53 gene mutations in gastric carcinoma detected by polymerase chain reaction/single-strand conformation polymorphism analysis of archival material. J Cancer Res Clin Oncol 1995;121:79-83. [PMID: 7883779 DOI: 10.1007/BF01202217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Kubicka S, Claas C, Staab S, Kühnel F, Zender L, Trautwein C, Wagner S, Rudolph KL, Manns M. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci. 2002;47:114-121. [PMID: 11837710 DOI: 10.1023/a:1013275706401] [Cited by in Crossref: 41] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
43 Glasgow SC, Bleier JI, Burgart LJ, Finne CO, Lowry AC. Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases. J Gastrointest Surg. 2012;16:1019-1028. [PMID: 22258880 DOI: 10.1007/s11605-012-1827-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
44 Deveci MS, Deveci G. Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer. 2007;10:112-116. [PMID: 17577621 DOI: 10.1007/s10120-007-0418-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
45 McKay JA, Douglas JJ, Ross VG, Curran S, Loane JF, Ahmed FY, Cassidy J, McLeod HL, Murray GI. Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol. 2002;196:386-393. [PMID: 11920733 DOI: 10.1002/path.1053] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.0] [Reference Citation Analysis]
46 Rüschoff J, Bocker T, Vogel P, Schlegel J. Prognostic Significance of Molecular Biological and Immunohistological Parameters in Gastrointestinal Carcinomas. In: Kreuser E, Schlag PM, editors. New Perspectives in Molecular and Clinical Management of Gastrointestinal Tumors. Berlin: Springer Berlin Heidelberg; 1996. pp. 73-88. [DOI: 10.1007/978-3-642-80035-1_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
47 Sun X, Carstensen JM, Stål O, Zhang H, Nilsson E, Sjödahl R, Nordenskjöld B. Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma. Vichows Archiv A Pathol Anat 1993;423:443-8. [DOI: 10.1007/bf01606533] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
48 Anwar S, Frayling IM, Scott NA, Carlson GL. Systematic review of genetic influences on the prognosis of colorectal cancer. British Journal of Surgery 2004;91:1275-91. [DOI: 10.1002/bjs.4737] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
49 Lee WJ, Shun CT, Hong RL, Wu MS, Chang KJ, Chen KM. Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br J Surg. 1998;85:1138-1142. [PMID: 9718015 DOI: 10.1046/j.1365-2168.1998.00712.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
50 Kolodziejczyk P, Yao T, Oya M, Nakamura S, Utsunomiya T, Ishikawa T, Tsuneyoshi M. Long-term follow-up study of patients with gastric adenomas with malignant transformation. An immunohistochemical and histochemical analysis. Cancer. 1994;74:2896-2907. [PMID: 7954254 DOI: 10.1002/1097-0142(19941201)74:11%3C2896::AID-CNCR2820741103%3E3.0.CO;2-P] [Reference Citation Analysis]
51 Tollenaar RA, van Krieken JH, van Slooten HJ, Bruinvels DJ, Nelemans KM, van den Broek LJ, Hermans J, van Dierendonck JH. Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance. Br J Cancer 1998;77:1842-7. [PMID: 9667656 DOI: 10.1038/bjc.1998.306] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 1.8] [Reference Citation Analysis]
52 Starzynska T, Markiewski M, Domagala W, Marlicz K, Mietkiewski J, Roberts SA, Stern PL. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 1996;77:2005-12. [DOI: 10.1002/(sici)1097-0142(19960515)77:10<2005::aid-cncr7>3.0.co;2-p] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
53 Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 1996;74:216-23. [PMID: 8688324 DOI: 10.1038/bjc.1996.340] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 2.3] [Reference Citation Analysis]
54 Kim MJ, Kim H. Anticancer Effect of Lycopene in Gastric Carcinogenesis. J Cancer Prev 2015;20:92-6. [PMID: 26151041 DOI: 10.15430/JCP.2015.20.2.92] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
55 Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R, Rahamin J, Alderson D. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol. 1997;23:30-35. [PMID: 9066744 DOI: 10.1016/s0748-7983(97)80139-4] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
56 Xie XF, Yang Q, Chi J, Yang XZ, Wang HY, Xu GL. Prognostic values of apoptosis-stimulating P53-binding protein 1 and 2 and their relationships with clinical characteristics of esophageal squamous cell carcinoma patients: a retrospective study. Chin J Cancer 2017;36:15. [PMID: 28103919 DOI: 10.1186/s40880-016-0169-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Osen, Fossa, Majak, Rotterud, Berner. Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. BJU Int 1998;81:862-9. [DOI: 10.1046/j.1464-410x.1998.00657.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kang S, Maeda K, Onoda N, Chung Y, Nakata B, Nishiguchi Y, Sowa M. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 1997;74:502-7. [DOI: 10.1002/(sici)1097-0215(19971021)74:5<502::aid-ijc4>3.0.co;2-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
59 Nuvoli B, Santoro R, Catalani S, Battistelli S, Benedetti S, Canestrari F, Galati R. CELLFOOD™ induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways. J Exp Clin Cancer Res 2014;33:24. [PMID: 24598211 DOI: 10.1186/1756-9966-33-24] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
60 Chien C, Huang C, Cheng J, Chen C, Hwang C, Su C. The clinicopathological significance of p53 and p21 expression in squamous cell carcinoma of hypopharyngeal cancer. Cancer Letters 2003;201:217-23. [DOI: 10.1016/s0304-3835(03)00484-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
61 Ikeguchi M, Oka S, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N. Computerized nuclear morphometry: a new morphologic assessment for advanced gastric adenocarcinoma. Ann Surg 1999;229:55-61. [PMID: 9923800 DOI: 10.1097/00000658-199901000-00007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
62 Rojansky N, Shushan A, Livni N, Jurim O, Sulam M, Galun E. Pregnancy associated with colon carcinoma overexpressing p53. Gynecol Oncol. 1997;64:516-520. [PMID: 9062163 DOI: 10.1006/gyno.1996.4549] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
63 Pritchard DM, Watson AJ. Apoptosis and gastrointestinal pharmacology. Pharmacol Ther. 1996;72:149-169. [PMID: 8981574 DOI: 10.1016/s0163-7258(96)00102-7] [Cited by in Crossref: 53] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
64 Ikawa-Yoshida A, Ando K, Oki E, Saeki H, Kumashiro R, Taketani K, Ida S, Tokunaga E, Kitao H, Morita M, Maehara Y. Contribution of BubR1 to oxidative stress-induced aneuploidy in p53-deficient cells. Cancer Med 2013;2:447-56. [PMID: 24156017 DOI: 10.1002/cam4.101] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
65 Keith FJ, Russell NH. The role of p53 in malignancy. In: Freireich EJ, Kantarjian H, editors. Molecular Genetics and Therapy of Leukemia. Boston: Springer US; 1996. pp. 113-37. [DOI: 10.1007/978-1-4613-1261-1_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Igarashi N, Takahashi M, Ohkubo H, Omata K, Iida R, Fujimoto S. Predictive value of Ki-67, p53 protein, and DNA content in the diagnosis of gastric carcinoma. Cancer 1999;86:1449-54. [DOI: 10.1002/(sici)1097-0142(19991015)86:8<1449::aid-cncr10>3.0.co;2-d] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
67 Kuczyk MA, Serth J, Bokemeyer C, Jonassen J, Machtens S, Werner M, Jonas U. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis. Cancer 1996;78:1958-66. [DOI: 10.1002/(sici)1097-0142(19961101)78:9<1958::aid-cncr17>3.0.co;2-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
68 Zullo A, Romiti A, Rinaldi V, Vecchione A, Tomao S, Aiuti F, Frati L, Luzi G. Gastric pathology in patients with common variable immunodeficiency. Gut 1999;45:77-81. [PMID: 10369708 DOI: 10.1136/gut.45.1.77] [Cited by in Crossref: 86] [Cited by in F6Publishing: 60] [Article Influence: 3.9] [Reference Citation Analysis]
69 Wiggenraad R, Tamminga R, Blok P, Rouse R, Hermans J. The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:29-35. [PMID: 9588914 DOI: 10.1016/s0360-3016(98)00043-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
70 Tuna B, Yörükoğlu K, Tüzel E, Güray M, Mungan U, Kirkali Z. Expression of p53 and mdm2 and Their Significance in Recurrence of Superficial Bladder Cancer. Pathology - Research and Practice 2003;199:323-8. [DOI: 10.1078/0344-0338-00424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
71 Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat. 2003;21:258-270. [PMID: 12619111 DOI: 10.1002/humu.10180] [Cited by in Crossref: 160] [Cited by in F6Publishing: 129] [Article Influence: 8.9] [Reference Citation Analysis]
72 Dowell SP, Hall PA. The clinical relevance of the p53 tumour suppressor gene. Cytopathology 1994;5:133-45. [PMID: 7919056 DOI: 10.1111/j.1365-2303.1994.tb00409.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
73 Nitti D, Belluco C, Montesco M, Bertorelle R, Da Pian P, Fassina A, Ninfo V, Chieco-bianchi L, Lise M. Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer: an independent prognostic factor of survival. European Journal of Cancer 1998;34:851-5. [DOI: 10.1016/s0959-8049(97)10165-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
74 Kitayama Y, Sugimura H, Tanaka M, Nakamura S, Kino I. Expression of p53 and flow cytometric DNA analysis of isolated neoplastic glands of the stomach: an application of the gland isolation method. Virchows Arch 1995;426:557-62. [PMID: 7655735 DOI: 10.1007/BF00192109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
75 Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H, Brown D, Srivastava S, Grizzle WE. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 1997;74:346-58. [DOI: 10.1002/(sici)1097-0215(19970620)74:3<346::aid-ijc19>3.0.co;2-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
76 Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, Neifeld JP. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994;73:181-6. [PMID: 8275422 DOI: 10.1002/1097-0142(19940101)73:1<181::aid-cncr2820730131>3.0.co;2-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
77 Diez M, Enriquez JM, Camuñas J, Gonzalez A, Gutierrez A, Mugüerza JM, Ruiz A, Granell J. Prediction of recurrence in B-C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features. Eur J Surg Oncol 1995;21:635-9. [PMID: 8631411 DOI: 10.1016/s0748-7983(95)95477-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
78 Baretton GB, Vogt M, Müller C, Diebold J, Schneiderbanger K, Schmidt M, Löhrs U. Prognostic Significance of p53 Expression, Chromosome 17 Copy Number, and DNA Ploidy in Non-Metastasized Colorectal Carcinomas (Stages IB and II). Scandinavian Journal of Gastroenterology 2009;31:481-9. [DOI: 10.3109/00365529609006769] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
79 De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, Peeters PM, Slooff MJ, De Vries EG. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology. 1998;28:971-979. [PMID: 9755233 DOI: 10.1002/hep.510280411] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 3.4] [Reference Citation Analysis]
80 Stemmermann G, Heffelfinger SC, Noffsinger A, Hui YZ, Miller MA, Fenoglio-Preiser CM. The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors. Hum Pathol. 1994;25:968-981. [PMID: 7927320 DOI: 10.1016/0046-8177(94)90056-6] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 3.0] [Reference Citation Analysis]
81 Kolodziejczyk P, Yao T, Oya M, Nakamura S, Utsunomiya T, Ishikawa T, Tsuneyoshi M. Long term follow-up study of patients with gastric adenomas with malignant transformation. An immunohistochemical and histochemical analysis. Cancer 1994;74:2896-907. [DOI: 10.1002/1097-0142(19941201)74:11<2896::aid-cncr2820741103>3.0.co;2-p] [Cited by in Crossref: 43] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
82 Torén W, Ansari D, Andersson R. Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis. Cancer Cell Int 2018;18:217. [PMID: 30602942 DOI: 10.1186/s12935-018-0715-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Rocha FTR, Lourenço LG, Jucá MJ, Leal AT, Paz AMDCD. Expressão da proteína P53 no adenocarcinoma gástrico: correlação clínica, anatomopatológica e significância prognostica. Rev Col Bras Cir 2004;31:186-93. [DOI: 10.1590/s0100-69912004000300008] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
84 Poller DN, Baxter KJ, Shepherd NA. p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 1997;75:87-93. [PMID: 9000603 DOI: 10.1038/bjc.1997.14] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 2.0] [Reference Citation Analysis]
85 Dix BR, Robbins P, Soong R, Jenner D, House AK, Iacopetta BJ. The common molecular genetic alterations in Dukes’ B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer. 1994;59:747-751. [PMID: 7989112 DOI: 10.1002/ijc.2910590606] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 3.2] [Reference Citation Analysis]
86 Lashner BA, Shapiro BD, Husain A, Goldblum JR. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol 1999;94:456-62. [PMID: 10022646 DOI: 10.1111/j.1572-0241.1999.877_f.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 3.0] [Reference Citation Analysis]
87 Mulder JW, Baas IO, Polak MM, Goodman SN, Offerhaus GJ. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995;71:1257-62. [PMID: 7779721 DOI: 10.1038/bjc.1995.243] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 1.7] [Reference Citation Analysis]
88 Adrover E, Maestro ML, Sanz-Casla MT, del Barco V, Cerdán J, Fernández C, Balibrea JL. Expression of high p53 levels in colorectal cancer: a favourable prognostic factor. Br J Cancer 1999;81:122-6. [PMID: 10487622 DOI: 10.1038/sj.bjc.6690660] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
89 Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis. 2003;18:518-525. [PMID: 12811476 DOI: 10.1007/s00384-003-0491-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
90 Chapkin RS, Lupton JR. Colonic Cell Proliferation and Apoptosis in Rodent Species. Colon Cancer Prevention. Boston: Springer US; 1999. pp. 105-18. [DOI: 10.1007/978-1-4615-4149-3_12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
91 Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer: PROGNOSTIC FACTORS IN GASTRIC CANCER. Br J Surg 1997;84:1651-64. [DOI: 10.1046/j.1365-2168.1997.00619.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
92 Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. European Journal of Cancer 1993;29:2077-9. [DOI: 10.1016/0959-8049(93)90036-f] [Cited by in Crossref: 59] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
93 D'Errico A, Grigioni WF, Fiorentino M, Baccarini P, Grazi GL, Mancini AM. Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma: an immunohistochemical study on 109 Italian patients. Pathol Int. 1994;44:682-687. [PMID: 7804430 DOI: 10.1111/j.1440-1827.1994.tb02947.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
94 De Torres I, Fortuno M, Raventos A, Tarragona J, Banus J, Vidal M. Primary Malignant Melanoma of the Bladder: Immunohistochemical Study of a New Case and Review of the Literature. Journal of Urology 1995;154:525-7. [DOI: 10.1016/s0022-5347(01)67094-0] [Cited by in Crossref: 9] [Article Influence: 0.3] [Reference Citation Analysis]
95 Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg. 1997;84:1651-1664. [PMID: 9448610 DOI: 10.1002/bjs.1800841206] [Cited by in Crossref: 60] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
96 Yao T, Utsunomiya T, Oya M, Nishiyama K, Tsuneyoshi M. Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features. World J Gastroenterol. 2006;12:2510-2516. [PMID: 16688795 DOI: 10.3748/wjg.v12.i16.2510] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
97 Victorzon M, Nordling S, Haglund C, Lundin J, Roberts P. Expression of p53 protein as a prognostic factor in patients With gastric cancer. European Journal of Cancer 1996;32:215-20. [DOI: 10.1016/0959-8049(95)00547-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
98 Kuczyk M, Serth J, Bokemeyer C, Allhoff E, Jonassen J, Kuczyk S, Jonas U. Over expression of the P53 Oncoprotein in Carcinoma in Situ of the Testis. Pathology - Research and Practice 1994;190:993-8. [DOI: 10.1016/s0344-0338(11)80892-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
99 Ito H, Ishida M, Ohfuji S, Osaki M, Hayashi H, Tatebe S. Stomach Cancer and Apoptosis: A Review. In: Tahara E, editor. Molecular Pathology of Gastroenterological Cancer. Tokyo: Springer Japan; 1997. pp. 81-92. [DOI: 10.1007/978-4-431-65915-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
100 Wilson R, Whiteside M, Russell S. Molecular genetics of colorectal cancer (part 1). Clinical Oncology 1997;9:14-9. [DOI: 10.1016/s0936-6555(97)80052-0] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
101 Skilling JS. COLORECTAL CANCER COMPLICATING PREGNANCY. Obstetrics and Gynecology Clinics of North America 1998;25:417-21. [DOI: 10.1016/s0889-8545(05)70015-2] [Cited by in Crossref: 17] [Article Influence: 0.7] [Reference Citation Analysis]
102 Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum. 2004;47:1798-1807. [PMID: 15622571 DOI: 10.1007/s10350-004-0681-1] [Cited by in Crossref: 114] [Cited by in F6Publishing: 97] [Article Influence: 7.1] [Reference Citation Analysis]
103 McCulloch P, Taggart T, Ochiai A, O’Dowd G, Nash J, Sasako M. c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan. Eur J Surg Oncol. 1997;23:304-309. [PMID: 9315057 DOI: 10.1016/s0748-7983(97)90669-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
104 Nagai E, Yao T, Sakamoto M, Akazawa K, Utsunomiya T, Tsuneyoshi M. Risk factors related to liver metastasis in colorectal carcinoma: a multivariate analysis of clinicopathologic and immunohistochemical variables. Jpn J Cancer Res 1994;85:1280-7. [PMID: 7531682 DOI: 10.1111/j.1349-7006.1994.tb02941.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
105 Weiss J, Heine M, Körner B, Pilch H, Jung EG. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol 1995;133:23-31. [PMID: 7669636 DOI: 10.1111/j.1365-2133.1995.tb02487.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.2] [Reference Citation Analysis]
106 Norberg T, Jansson T, Sjoügren S, Mårtensson C, Andréasson I, Fjaüllskog M, Lindman H, Nordgren H, Lindgren A, Holmberg L, Bergh J. Overview on Human Breast Cancer with Focus on Prognostic and Predictive Factors with Special Attention on the Tumour Suppressor Gene P53. Acta Oncologica 2009;35:96-102. [DOI: 10.3109/02841869609083980] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
107 el-Mahdani N, Vaillant JC, Guiguet M, Prévot S, Bertrand V, Bernard C, Parc R, Béréziat G, Hermelin B. Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. Br J Cancer 1997;75:528-36. [PMID: 9052405 DOI: 10.1038/bjc.1997.92] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
108 Mcculloch PG, Ochiai A, Hirohashi S, O'dowd GM, Nash JRG, Sasako M. Comparison of the molecular genetics ofc-erb-B2 and p53 expression in stomach cancer in Britain and Japan. Cancer 1995;75:920-5. [DOI: 10.1002/1097-0142(19950215)75:4<920::aid-cncr2820750405>3.0.co;2-e] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
109 Hammel P, Boissier B, Chaumette MT, Piedbois P, Rotman N, Kouyoumdjian JC, Lubin R, Delchier JC, Soussi T. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 1997;40:356-61. [PMID: 9135525 DOI: 10.1136/gut.40.3.356] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 2.4] [Reference Citation Analysis]
110 Chang M, Chong I, Chen F, Wang J, Cheng T, Cheng Y, Sheu CC, Hung S, Yang M, Lin S. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer. Cancer Letters 2005;222:195-204. [DOI: 10.1016/j.canlet.2004.11.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
111 Ken-ichi Nibu, Akio Yanagisawa, Mun. Clinical Role of p53 and p21 WAF1/CIP1 in Squamous Cell Carcinoma of the Pyriform Sinus. Acta Oto-Laryngologica 2009;118:432-7. [DOI: 10.1080/00016489850183575] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
112 Cho SH, Seung BJ, Kim SH, Lim HY, Sur JH. Overexpression and Mutation of p53 Exons 4-8 in Canine Intestinal Adenocarcinoma. J Comp Pathol 2020;175:79-84. [PMID: 32138847 DOI: 10.1016/j.jcpa.2019.12.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
113 Liu XP, Tsushimi K, Tsushimi M, Kawauchi S, Oga A, Furuya T, Sasaki K. Expression of p21WAF1/CIP1 and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Letters 2001;170:183-9. [DOI: 10.1016/s0304-3835(01)00589-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
114 Hamelin R, Laurent-puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8. [DOI: 10.1016/s0016-5085(94)94217-x] [Cited by in Crossref: 237] [Cited by in F6Publishing: 56] [Article Influence: 8.8] [Reference Citation Analysis]
115 Igarashi N, Takahashi M, Ohkubo H, Omata K, Iida R, Fujimoto S. Predictive value of Ki-67, p53 protein, and DNA content in the diagnosis of gastric carcinoma. Cancer 1999;86:1449-54. [DOI: 10.1002/(sici)1097-0142(19991015)86:8<1449::aid-cncr10>3.0.co;2-d] [Reference Citation Analysis]
116 Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N, Ito H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997;79:2067-72. [DOI: 10.1002/(sici)1097-0142(19970601)79:11<2067::aid-cncr3>3.0.co;2-m] [Cited by in Crossref: 67] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
117 Babacan NA, Egilmez HR, Yücel B, Ilknur P, Seker MM, Kacan T, Bahceci A, Cihan S, Akinci B, Eriten B, Kilickap S. The prognostic value of UHRF-1 and p53 in gastric cancer. Saudi J Gastroenterol 2016;22:25-9. [PMID: 26831603 DOI: 10.4103/1319-3767.173755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
118 Saberi Anvar M, Minuchehr Z, Shahlaei M, Kheitan S. Gastric cancer biomarkers; A systems biology approach. Biochem Biophys Rep 2018;13:141-6. [PMID: 29556568 DOI: 10.1016/j.bbrep.2018.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
119 Sinicrope FA, Hart J, Brasitus TA, Michelassi F, Lee JJ, Safa AR. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer 1994;74:2908-17. [PMID: 7954255 DOI: 10.1002/1097-0142(19941201)74:11<2908::aid-cncr2820741104>3.0.co;2-m] [Cited by in Crossref: 33] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
120 Dix B, Robbins P, Carrello S, House A, Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer. 1994;70:585-590. [PMID: 7917901 DOI: 10.1038/bjc.1994.355] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 3.2] [Reference Citation Analysis]
121 Ofner D, Maier H, Riedmann B, Holzberger P, Nogler M, Tötsch M, Bankfalvi A, Winde G, Böcker W, Schmid KW. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. Clin Mol Pathol 1995;48:M12-6. [PMID: 16695968 DOI: 10.1136/mp.48.1.m12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
122 Hollstein M, Soussi T, Thomas G, von Brevern MC, Bartsch. P53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 1997;143:369-89. [PMID: 8912433 DOI: 10.1007/978-3-642-60393-8_26] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.5] [Reference Citation Analysis]
123 Kim YJ, Kim MA, Im SA, Kim TM, Kim DW, Yang HK, Heo DS, Lee KU, Choe KJ, Kim NK. Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer. Cancer Invest. 2008;26:152-158. [PMID: 18259945 DOI: 10.1080/07357900701518909] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
124 Stem HS. Contributions of molecular genetics to the clinical management of colorectal cancer. The American Journal of Surgery 1996;171:10-5. [DOI: 10.1016/s0002-9610(99)80065-8] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
125 Kopp R, Diebold J, Dreier I, Cramer C, Glas J, Baretton G, Jauch KW. Prognostic relevance of p53 and bcl-2 immunoreactivity for early invasive pT1/pT2 gastric carcinomas: indicators for limited gastric resections? Surg Endosc 2005;19:1507-12. [DOI: 10.1007/s00464-005-0043-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
126 Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta 1993;1155:181-205. [PMID: 8357826 DOI: 10.1016/0304-419x(93)90004-v] [Cited by in Crossref: 23] [Cited by in F6Publishing: 59] [Article Influence: 0.8] [Reference Citation Analysis]
127 Gestl EE, Anne Böttger S. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines. Biochemical and Biophysical Research Communications 2012;423:411-6. [DOI: 10.1016/j.bbrc.2012.05.139] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
128 Slebos RJ, Baas IO, Clement M, Polak M, Mulder JW, van den Berg FM, Hamilton SR, Offerhaus GJ. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer 1996;74:165-71. [PMID: 8688317 DOI: 10.1038/bjc.1996.333] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 1.6] [Reference Citation Analysis]
129 Gürel S, Dolar E, Yerci Ö, Samli B, Öztürk H, Nak S, Gülten M, Memik F. Expression of p53 Protein and Prognosis in Gastric Carcinoma. J Int Med Res 1999;27:85-9. [DOI: 10.1177/030006059902700205] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
130 Teh M, Sun Lee Y. An immunohistochemical study of p53 protein in the different histological subtypes of gastric carcinoma. Pathology 1994;26:432-4. [DOI: 10.1080/00313029400169142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
131 Imai Y. Poorly differentiated adenocarcinoma of the colon: subsite location and clinicopathologic features. Int J Colorectal Dis 2015;30:187-96. [PMID: 25416528 DOI: 10.1007/s00384-014-2070-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
132 Papanastassiou I, Ioannou M, Papagelopoulos PJ, Arealis G, Mihas C, Iakovidou I, Demertzis N. P53 expression as a prognostic marker in giant cell tumor of bone: a pilot study. Orthopedics 2010;33. [PMID: 20506947 DOI: 10.3928/01477447-20100329-15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
133 Carethers JM, Jung BH. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology 2015; 149: 1177-1190. e3. [PMID: 26216840 DOI: 10.1053/j.gastro.2015.06.047] [Cited by in Crossref: 198] [Cited by in F6Publishing: 173] [Article Influence: 33.0] [Reference Citation Analysis]
134 Bradley BA, Evers B. Molecular advances in the etiology and treatment of colorectal cancer. Surgical Oncology 1997;6:143-56. [DOI: 10.1016/s0960-7404(97)00020-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
135 Brett MC, Pickard M, Green B, Howel-Evans A, Smith D, Kinsella A, Poston G. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 1996;22:182-5. [PMID: 8608838 DOI: 10.1016/s0748-7983(96)90827-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
136 Sheridan E, Silcocks P, Smith J, Hancock B, Goyns M. P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. European Journal of Cancer 1994;30:1701-4. [DOI: 10.1016/0959-8049(94)00325-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
137 Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, Sugimachi K. Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis. Br J Cancer 1999;79:1255-61. [PMID: 10098768 DOI: 10.1038/sj.bjc.6690201] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
138 Itzkowitz SH, Greenwald B, Meltzer SJ. Colon Carcinogenesis in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 1995;1:142-58. [DOI: 10.1097/00054725-199506000-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
139 Bhatavdekar JM, Patel DD, Ghosh N, Chikhlikar PR, Trivedi TI, Suthar TP, Doctor SS, Shah NG, Balar DB. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Diseases of the Colon & Rectum 1997;40:785-90. [DOI: 10.1007/bf02055433] [Cited by in Crossref: 53] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
140 Ramnani DM, Wistuba II, Behrens C, Gazdar AF, Sobin LH, Albores-saavedra J. K-ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix. Cancer 1999;86:14-21. [DOI: 10.1002/(sici)1097-0142(19990701)86:1<14::aid-cncr4>3.0.co;2-x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
141 Lacueva FJ, Calpena R, Medrano J, Teruel A, Mayol MJ, Graells ML, Camarasa MV, Perez-vazquez MT, Ferragut JA. Changes in P-glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53. Cancer 2000;89:21-8. [DOI: 10.1002/1097-0142(20000701)89:1<21::aid-cncr4>3.0.co;2-t] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
142 Tech M, Wee A, Raju GC. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. Cancer 1994;74:1542-5. [DOI: 10.1002/1097-0142(19940901)74:5<1542::aid-cncr2820740508>3.0.co;2-u] [Cited by in Crossref: 52] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
143 Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003;21:271-6. [DOI: 10.1002/humu.10175] [Cited by in Crossref: 192] [Cited by in F6Publishing: 158] [Article Influence: 10.7] [Reference Citation Analysis]
144 Grewal H, Guillem JG, Klimstra DS, Cohen AM. p53 Nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Diseases of the Colon & Rectum 1995;38:1176-81. [DOI: 10.1007/bf02048333] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
145 Fléjou JF, Muzeau F, Potet F, Lepelletier F, Fékété F, Hénin D. Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas. Pathol Res Pract. 1994;190:1141-1148. [PMID: 7540752 DOI: 10.1016/s0344-0338(11)80440-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
146 F. Clausen OP, Lothe RA, Børresen-dale A, Angelis PD, Chen Y, Rognum TO, Meling GI. Association of p53 Accumulation With TP53 Mutations, Loss of Heterozygosity at 17p13, and DNA Ploidy Status in 273 Colorectal Carcinomas: . Diagnostic Molecular Pathology 1998;7:215-23. [DOI: 10.1097/00019606-199808000-00006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
147 Leahy DT, Salman R, Mulcahy H, Sheahan K, O'donoghue DP, Parfrey NA. PROGNOSTIC SIGNIFICANCE OF p53 ABNORMALITIES IN COLORECTAL CARCINOMA DETECTED BY PCR-SSCP AND IMMUNOHISTOCHEMICAL ANALYSIS. J Pathol 1996;180:364-70. [DOI: 10.1002/(sici)1096-9896(199612)180:4<364::aid-path683>3.0.co;2-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
148 Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76:720-6. [DOI: 10.1002/1097-0142(19950901)76:5<720::aid-cncr2820760503>3.0.co;2-e] [Cited by in Crossref: 73] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
149 Tsujitani S, Saito H, Wakatsuki T, Ikeguchi M, Shirabe K, Morita M, Kakeji Y, Yano T, Maehara Y. Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today. 2012;42:225-232. [PMID: 22143356 DOI: 10.1007/s00595-011-0062-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
150 Kros JM, Godschalk JJCJ, Krishnadath KK, Van Eden CG. Expression of p53 in oligodendrogliomas. J Pathol 1993;171:285-90. [DOI: 10.1002/path.1711710409] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]